Introdução: A fisiopatologia da doença de Parkinson está associada a lesões por estresse oxidativo/nitrosativo. O ferro encontra-se acumulado na substância negra (SN) de pacientes com DP e está relacionado com esse dano através das espécies reagentes de oxigênio (EROs) e de nitrogênio (ERNs) na reação de Fenton. EROs e ERNs são produzidas normalmente em processos celulares e inflamatórios, e controladas por sistemas antioxidantes. Objetivo: Avaliar níveis periféricos de ferro em pacientes com DP para determinar se acúmulo na SN está relacionado com níveis elevados no sangue. Determinar biomarcadores periféricos confiáveis de estresse oxidativo/nitrosativo Métodos: Selecionados 40 pacientes com DP e 46 indivíduos controles para comparar níveis séricos de ferro, ferritina e transferrina, e de biomarcadores de estresse oxidativo/nitrosativo: superóxido dismutase (SOD), catalase, óxido nítrico (NOx), substâncias reativas ao ácido tiobarbitúrico (TBARS), tióis não-proteicos, “advanced oxidation protein products” (AOPP), “ferric reducing ability of plasma” (FRAP), NTPDases, ecto-5’-nucleotidase, adenosina deaminase (ADA), mieloperoxidase, albumina modificada pela isquemia (IMA) e vitamina C. Resultados: Níveis de ferro estavam diminuídos em pacientes com DP, enquanto ferritina e transferrina não mostraram diferença. Os biomarcadores de estresse oxidativo como TBARS, AOPP, NTPDases, IMA, mieloperoxidase, FRAP, vitamina C e tiois não-proteicos encontraram-se significativamente aumentados na DP. SOD, catalase, ecto-5’-nucleotidase não foram diferentes entre os grupos e os marcadores NOx e ADA foram significativamente aumentados nos controles. Nenhuma correlação foi encontrada entre os biomarcadores e dados sociodemográficos e de características da doença. Conclusão: Níveis plasmáticos de ferro encontram-se diminuídos em pacientes com DP comparados com controles saudáveis. Os biomarcadores TBARS, AOPP, NTPDases, IMA e mieloperoxidase mostraram-se confiáveis para lesão oxidativa, enquanto tióis não-proteicos, FRAP e vitamina C demonstram diminuição da capacidade antioxidante na DP. / Background: Parkinson’s disease (PD) pathophysiology is associated with oxidative/nitrosative stress damage. Iron accumulates in the substantia nigra (SN) of PD patients and is related to this damage along with oxygen and nitrogen reactive species (ROS, RNS) through Fenton reaction. ROS and RNS are normally produced in cell and inflammatory processes, controlled by antioxidant systems. Objective: To determine peripheral levels of iron, ferritin and transferrin in PD patients to evaluate whether iron accumulation in the SN could be related to serum levels. To determine reliable peripheral biomarkers of oxidative/nitrative stress. Methods: Forty PD patients and 46 controls were selected to compared serum levels of iron, ferritin, transferrin and oxidative/nitrative stress biomarkers: superoxide dismutase (SOD), catalase, nitric oxide (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols, advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP), NTPDases, ecto-5’-nucleotidase, adenosine deaminase (ADA), myeloperoxidase, ischemic-modified albumin (IMA) and vitamin C. Results: Iron levels were decreased in patients with PD, while ferritin and transferrin were not different. Oxidative stress biomarkers, TBARS, AOPP, NTPDases, IMA, myeloperoxidase, FRAP, vitamin C and non-proteic thiols were significantly higher in PD. SOD, catalase, ecto-5’-nucleotidase were not different between the groups and biomarkers NOx and ADA were significantly increased in the controls. No correlation was found between biomarkers and sociodemographic and disease data. Conclusion: Plasmatic levels of iron are decreased in patients with PD compared to healthy controls. Biomarkers TBARS, AOPP, NTPDases, IMA and myeloperoxidase presented as reliable to measure oxidative/nitrative damage, while non-proteic thiols, FRAP and vitamin C show a decrease in the antioxidant capacity in PD.

Introdução: A fisiopatologia da doença de Parkinson está associada a lesões por estresse oxidativo/nitrosativo. O ferro encontra-se acumulado na substância negra (SN) de pacientes com DP e está relacionado com esse dano através das espécies reagentes de oxigênio (EROs) e de nitrogênio (ERNs) na reação de Fenton. EROs e ERNs são produzidas normalmente em processos celulares e inflamatórios, e controladas por sistemas antioxidantes. Objetivo: Avaliar níveis periféricos de ferro em pacientes com DP para determinar se acúmulo na SN está relacionado com níveis elevados no sangue. Determinar biomarcadores periféricos confiáveis de estresse oxidativo/nitrosativo Métodos: Selecionados 40 pacientes com DP e 46 indivíduos controles para comparar níveis séricos de ferro, ferritina e transferrina, e de biomarcadores de estresse oxidativo/nitrosativo: superóxido dismutase (SOD), catalase, óxido nítrico (NOx), substâncias reativas ao ácido tiobarbitúrico (TBARS), tióis não-proteicos, “advanced oxidation protein products” (AOPP), “ferric reducing ability of plasma” (FRAP), NTPDases, ecto-5’-nucleotidase, adenosina deaminase (ADA), mieloperoxidase, albumina modificada pela isquemia (IMA) e vitamina C. Resultados: Níveis de ferro estavam diminuídos em pacientes com DP, enquanto ferritina e transferrina não mostraram diferença. Os biomarcadores de estresse oxidativo como TBARS, AOPP, NTPDases, IMA, mieloperoxidase, FRAP, vitamina C e tiois não-proteicos encontraram-se significativamente aumentados na DP. SOD, catalase, ecto-5’-nucleotidase não foram diferentes entre os grupos e os marcadores NOx e ADA foram significativamente aumentados nos controles. Nenhuma correlação foi encontrada entre os biomarcadores e dados sociodemográficos e de características da doença. Conclusão: Níveis plasmáticos de ferro encontram-se diminuídos em pacientes com DP comparados com controles saudáveis. Os biomarcadores TBARS, AOPP, NTPDases, IMA e mieloperoxidase mostraram-se confiáveis para lesão oxidativa, enquanto tióis não-proteicos, FRAP e vitamina C demonstram diminuição da capacidade antioxidante na DP. / Background: Parkinson’s disease (PD) pathophysiology is associated with oxidative/nitrosative stress damage. Iron accumulates in the substantia nigra (SN) of PD patients and is related to this damage along with oxygen and nitrogen reactive species (ROS, RNS) through Fenton reaction. ROS and RNS are normally produced in cell and inflammatory processes, controlled by antioxidant systems. Objective: To determine peripheral levels of iron, ferritin and transferrin in PD patients to evaluate whether iron accumulation in the SN could be related to serum levels. To determine reliable peripheral biomarkers of oxidative/nitrative stress. Methods: Forty PD patients and 46 controls were selected to compared serum levels of iron, ferritin, transferrin and oxidative/nitrative stress biomarkers: superoxide dismutase (SOD), catalase, nitric oxide (NOx), thiobarbituric acid reactive substances (TBARS), non-protein thiols, advanced oxidation protein products (AOPP), ferric reducing ability of plasma (FRAP), NTPDases, ecto-5’-nucleotidase, adenosine deaminase (ADA), myeloperoxidase, ischemic-modified albumin (IMA) and vitamin C. Results: Iron levels were decreased in patients with PD, while ferritin and transferrin were not different. Oxidative stress biomarkers, TBARS, AOPP, NTPDases, IMA, myeloperoxidase, FRAP, vitamin C and non-proteic thiols were significantly higher in PD. SOD, catalase, ecto-5’-nucleotidase were not different between the groups and biomarkers NOx and ADA were significantly increased in the controls. No correlation was found between biomarkers and sociodemographic and disease data. Conclusion: Plasmatic levels of iron are decreased in patients with PD compared to healthy controls. Biomarkers TBARS, AOPP, NTPDases, IMA and myeloperoxidase presented as reliable to measure oxidative/nitrative damage, while non-proteic thiols, FRAP and vitamin C show a decrease in the antioxidant capacity in PD.

Untersucht wurde der Zusammenhang zwischen der Proteinkinase A-vermittelten Ekto-Phosphorylierung des Membranproteins FAT/CD36 [Hatmi et al. 1996] und der initialen zellulären Aufnahme langkettiger Fettsäuren. Wir zeigten einen inhibitorischen Effekt auf die initiale Palmitinsäure-Aufnahme humaner Thrombozyten unter den Bedingungen der Ekto-Phosphorylierung von FAT/CD36. Damit kann erstmalig ein Mechanismus für die kurzfristige Regulation der proteinvermittelten Aufnahme langkettiger Fettsäuren vorgeschlagen werden. Für die Bearbeitung der Fragestellung wurden die Isolation "ruhender", morphologisch und funktionell intakter humaner Thrombozyten und eine Methode zur Messung der initialen Palmitinsäure-Aufnahme etabliert. Die Kinetik der Palmitinsäure-Aufnahme humaner Thrombozyten wurde charakterisiert und bestätigt, dass ein wesentlicher Anteil der initialen Aufnahme proteinvermittelt erfolgt. Die von Hatmi und Co-Autoren beschriebene Ekto-Proteinkinase A-vermittelte, cAMP-abhängige Phosphorylierung von FAT/CD36 [Hatmi et al. 1996] konnte unter unseren experimentellen Bedingungen nachvollzogen werden. Die Ekto-Phosphorylierung von FAT/CD36 ging mit einer signifikanten Abnahme der initialen Palmitinsäure-Aufnahme einher. Die maximale Abnahme auf 72 % des Kontrollwerts wurde bei einer extrazellulären ATP-Konzentration von 0,5 nM erreicht. Der inhibitorische Effekt liess sich durch Co-Inkubation mit dem spezifischen Proteinkinase A-Inhibitorpeptid PKI 5-24 oder mit beta-gamma-ATP aufheben. Der Effekt war durch Dephosphorylierung mit Alkalischer Phosphatase vollständig reversibel. Bei extrazellulären ATP-Konzentrationen zwischen 10 pM und 15 nM war der inhibitorische Effekt der Ekto-Phosphorylierung auf die Palmitinsäure-Aufnahme signifikant. ATP-Konzentrationen über 15 nM verminderten den Effekt, bei über 5 µM ATP war kein Effekt nachzuweisen. Wir konnten ausschliessen, dass die Aufhebung durch ATP-Abbauprodukte verursacht wurde. Unsere Beobachtungen deuten auf einen regulatorischen Einfluss höherer extrazellulärer ATP-Konzentrationen, der dem inhibitorischen Effekt der Ektophosphorylierung von FAT/CD36 auf die Fettsäure-Aufnahme entgegenwirkt. / We investigated the correlation between the ecto-protein kinase A-mediated phosphorylation of the membrane-associated protein FAT/CD36 [Hatmi et al. 1996] and the initial cellular long chain fatty acid uptake. Under the conditions of FAT/CD36-ecto-phosphorylation, an inhibitory effect on the initial palmitate uptake of human platelets could be shown. This is the first time that a mechanism for the short-term regulation of protein-mediated long chain fatty acid uptake can be proposed. The isolation of morphologically and functionally intact resting human platelets and a method for measuring the initial palmitate uptake were established. The kinetics of palmitate uptake by human platelets were characterised and it was shown that a substantial fraction of initial palmitate uptake is protein-mediated. The ecto-protein kinase A-mediated, cAMP-dependent phosphorylation of FAT/CD36 as described by Hatmi and co-authors could be demonstrated under our experimental conditions. The ecto-phosphorylation of FAT/CD36 was paralleled by a significant impairment of the initial palmitate uptake. Maximum inhibition was achieved at 0,5 nM extracellular ATP, when the palmitate uptake was decreased to 72 % compared to control. The inhibition of palmitate uptake was abolished by co-incubation with the specific protein kinase A inhibitor peptide PKI 5-24 or with beta-gamma-methylene-ATP, and was fully reversible upon addition of alkaline phosphatase. The inhibitory effect of the ecto-phosphorylation on the initial palmitate uptake was significant at extracellular ATP concentrations between 10 pM and 15 nM. ATP concentrations over 15 nM reduced the effect and concentrations over 5 µM completely abolished it. We could exclude that the abolishment was caused by ATP-derivates. Our data point to a regulatory influence of higher ATP concentrations, that antagonises the inhibitory effect of the ecto-phosphorylation of FAT/CD36 on the initial palmitate uptake.